S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
[Urgent!] Generational Wealth Gameplan (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Forget Nvidia, buy this A.I. Stock Now (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
[Urgent!] Generational Wealth Gameplan (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Forget Nvidia, buy this A.I. Stock Now (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
[Urgent!] Generational Wealth Gameplan (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Forget Nvidia, buy this A.I. Stock Now (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
[Urgent!] Generational Wealth Gameplan (Ad)
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Forget Nvidia, buy this A.I. Stock Now (Ad)
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Urgent alert: open this for a huge profit potential (Ad)
Stock market today: Asian shares gain despite Wall Street's tech-led retreat
Prologis Stock Leading U.S. Logistics Boom
Free Trial
NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)
Free TROV Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$4.20
▼
$5.25
50-Day Range
$1.19
▼
$24.71
52-Week Range
$0.70
▼
$3.46
Volume
2.16 million shs
Average Volume
648,892 shs
Market Capitalization
$50.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
TROV stock logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

TROV Stock News Headlines

February 23, 2024 | benzinga.com
Cardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and Dates
September 29, 2023 | markets.businessinsider.com
Cardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating Recommendation
April 18, 2024 | Daily Market Alerts (Ad)
Top 5 Tech Stocks to Buy for 2024
Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.
September 26, 2023 | marketwatch.com
Stocks to Watch: MillerKnoll, Cardiff Oncology, Morphic Holdings
August 8, 2023 | marketwatch.com
Cardiff Oncology Shares Up 26% After Potential Cancer Treatment Advances
August 8, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
May 27, 2023 | fool.com
Cardiff Oncology (NASDAQ: CRDF)
January 13, 2023 | forbes.com
Cardiff Oncology
April 18, 2024 | Daily Market Alerts (Ad)
Top 5 Tech Stocks to Buy for 2024
Elon Musk just Triggered a BOOM in These Stocks Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk.
December 14, 2022 | seekingalpha.com
Cardiff Oncology: Staying The Course
October 16, 2022 | markets.businessinsider.com
Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying
September 29, 2022 | finance.yahoo.com
Cardiff Oncology, Inc. (CRDF)
September 24, 2022 | seekingalpha.com
CRDF Cardiff Oncology, Inc.
August 25, 2022 | msn.com
Looking Into Cardiff Oncology's Return On Capital Employed
August 22, 2022 | seekingalpha.com
Cardiff Oncology: Down But Not Out
July 28, 2022 | finance.yahoo.com
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 31, 2022 | stocknews.com
5 Oncology Stocks Wall Street Predicts Will Rally 135% or More
March 22, 2022 | prnewswire.com
Cardiff Oncology to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC
August 5, 2021 | prnewswire.com
Cardiff Oncology Reports Second Quarter 2021 Results and Provides Business Updates
See More Headlines
Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2020
Today
4/17/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
CUSIP
N/A
CIK
1213037
Web
www.trovagene.com
Phone
(858) 952-7570
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A
Return on Equity
-202.00%
Return on Assets
-122.92%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
2.37
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$250,000.00
Price / Sales
202.16
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
4.88

Miscellaneous

Outstanding Shares
11,011,000
Free Float
N/A
Market Cap
$50.54 million
Optionable
Not Optionable
Beta
1.04
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

  • Mark Erlander
    Chief Executive Officer & Director
  • Vicki Kelemen
    Chief Operating Officer & Executive Vice President
  • Brigitte Lindsay
    Secretary & Vice President-Finance

Key Competitors

View All Competitors

TROV Stock Analysis - Frequently Asked Questions

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. Cardiff Oncology had a negative trailing twelve-month return on equity of 202.00% and a negative net margin of 3,688.31%.

When did Cardiff Oncology's stock split?

Cardiff Oncology's stock reverse split on the morning of Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

This page (NASDAQ:TROV) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
He Is Giving Away Bitcoin
Crypto Swap Profits
The “Perfect Storm” for Gold
Gold Safe Exchange
Urgent alert: open this for a huge profit potential
Timothy Sykes
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts
Biden out June 13; Kamala won’t replace him?
Paradigm Press
The #1 Crypto for 2024
InvestorPlace